

Clinical characteristics of 25 death cases with COVID-19: a retrospective review of medical records in a single medical center, Wuhan, China

Xun Li¹, Luwen Wang¹, Shaonan Yan¹, Fan Yang¹, Longkui Xiang¹, Jiling Zhu¹, Bo Shen^{2*}, Zuojiong Gong^{1*}

¹ Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan, China

² Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China

*Correspondence to: Prof. Zuojiong Gong, M.D. Ph.D., Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan 430060, China. E-mail: zjgong@163.com; Bo Shen, Ph.D., Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China. E-mail: 574190062@qq.com.

Summary

Background The pneumonia caused by the 2019 novel coronavirus (SARS-CoV-2) is a highly infectious disease, which was occurred in Wuhan, Hubei Province, China in December 2019. As of February 13, 2020, a total of 59883 cases of COVID-19 in China have been confirmed and 1368 patients have died from the disease. However, the clinical characteristics of the dyed patients were still not clearly clarified. This study aims to summarize the clinical characteristics of death cases with COVID-19 and to identify critically ill patients of COVID-19 early and reduce their mortality.

Methods The clinical records, laboratory findings and radiologic assessments included chest X-ray or computed tomography were extracted from electronic medical records of 25 died patients with COVID-19 in Renmin Hospital of Wuhan University from Jan 14 to Feb 13, 2020. Two experienced clinicians reviewed and abstracted the data.

Findings The mean age of the dead was 71.48 ± 12.42 years, the average course of the disease was 10.56 ± 4.42 days, all patients eventually died of respiratory failure. All of those who died had underlying diseases, the most common of which was hypertension (16/25, 64%), followed by diabetes (10/25, 40%), heart diseases (8/25, 32%), kidney diseases (5/25, 20%), cerebral infarction (4/25, 16%), chronic obstructive pulmonary disease (COPD, 2/25, 8%), malignant tumors (2/25, 8%) and acute pancreatitis (1/25, 4%). The most common organ damage outside the lungs was the heart, followed by kidney and liver. In the patients' last examination before death, white blood cell and neutrophil counts were elevated in 17 patients (17/25, 68%) and 18 patients (18/25, 72%), lymphocyte counts were decreased in 22 patients (22/25, 88%). Most patients' PCT, CRP and SAA levels were elevated, the percentages were 90.5% (19/21), 85% (19/20) and 100% (21/21) respectively. The levels of the last test of neutrophils (15/16, 93.8%), PCT (11/11, 100%), CRP (11/13, 84.6%), cTnI (8/9, 88.9%), D-Dimer (11/12, 91.6%) and LDH (9/9, 100%) were increased as compared to the first test, while the levels of lymphocytes were decreased (14/16, 87.5%).

Interpretation The age and underlying diseases (hypertension, diabetes, etc.) were the most

important risk factors for death of COVID-19 pneumonia. Bacterial infections may play an important role in promoting the death of patients. Malnutrition was common to severe patients. Multiple organ dysfunction can be observed, the most common organ damage was lung, followed by heart, kidney and liver. The rising of neutrophils, SAA, PCT, CRP, cTnI, D-Dimer and LDH levels can be used as indicators of disease progression, as well as the decline of lymphocytes counts.

Introduction

The pneumonia caused by the 2019 novel coronavirus (SARS-CoV-2) is a highly infectious disease, which was occurred in Wuhan, Hubei Province, China in December 2019 (1). It is reported that the person-to-person transmission in hospital and family settings has been accumulating (2-4). The patients' common clinical manifestations included fever, nonproductive cough, dyspnea, myalgia, fatigue, normal or decreased leukocyte counts, and radiographic evidence of pneumonia (5). Chen et al reported that mortality of COVID-19 was 4.3%, and severe cases (treated in the ICU) were older, more likely to have underlying comorbidities, dyspnea and anorexia (4). As of February 13, 2020, a total of 55748 cases of COVID-19 in China have been confirmed and 1380 patients have died from the disease (6). However, the clinical characteristics of the dyed patients were still not clearly clarified. In this study, we summarized the clinical characteristics of 25 death cases with COVID-19, the purpose is to identify critically ill patients of COVID-19 early and reduce their mortality.

Methods

Study design and patients

We performed a retrospective review of medical records from 25 death cases with COVID-19 in Renmin Hospital of Wuhan University from Jan 14 to Feb 13, 2020. All 25 dead patients with COVID-19 tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by use of RT-PCR on samples from there respiratory tract. Diagnosis of COVID-19 was based on the WHO's interim guidelines(7). This study was reviewed and approved by the Medical Ethical Committee of Renmin Hospital of Wuhan University.

Data collection

The clinical symptoms and signs, laboratory findings and radiologic assessments included chest X-ray or computed tomography were extracted from electronic medical records. Two experienced clinicians reviewed and abstracted the data. Data were entered into a computerized database and cross-checked. The criteria for the confirmed-diagnosis of SARS-CoV-2 was that at least one gene site was amplified to be positive for nucleocapsid protein (NP) gene and open reading frame (ORF)

lab gene. In brief, the throat swab was put into a collection tube containing 150 μ l viral preservation solution, and the total RNA was extracted within 2h with the respiratory sample RNA separation Kit (Zhongzhi, Wuhan). The suspension was used for RT-PCR assay of SARS-CoV-2 RNA. Two target genes, including NP and ORF1ab, were simultaneously amplified and tested during the real-time RT-PCR assay. Target 1 (NP): forward primer GGGGAACCTTCCTGCTAGAAT; reverse primer CAGACATTTTGCTCTC AAGCTG; and the probe 5'-FAM-TTGCTGCTGCTTGACAGATT-TAMRA-3'. Target 2 (ORF1ab): forward primer CCCTGTGGGTTTTACTTAA; reverse primer ACGATTGTGC ATCAGCTGA; and the probe 5'-VIC-CCGTCTGCGGTATGTGGAAAGGTTATGG-BHQ1 -3'. The real-time RT-PCR assay was performed using a 2019-nCoV nucleic acid detection kit according to the manufacturer's protocol (Shanghai bio-germ Medical Technology Co Ltd). Specific primers and probes for SARS-CoV-2 RNA detection were based on the recommendation by the National Institute for Viral Disease Control and Prevention (China) (http://ivdc.chinacdc.cn/kyjz/202001/t20200121_211337.html).

Statistical analysis

Statistical analysis was done with SPSS, version 20.0. Continuous variables were directly expressed as mean \pm SD. Categorical variables were expressed as number (%).

Results

General clinical characteristics

Of the 25 deaths, 10 were male and 15 were female. The mean age of the dead was 71.48 ± 12.42 years, range from 55 to 100 years. The average course of the disease was 10.56 ± 4.42 days, range from 4 to 20 days. All patients eventually died of respiratory failure and respirator was used in 23 patients (23/25, 92%). All (25/25, 100%) of those who died had underlying diseases, the most common of which was hypertension (16/25, 64%), followed by diabetes (10/25, 40%), heart diseases (8/25, 32%), kidney diseases (5/25, 20%), cerebral infarction (4/25, 16%), chronic obstructive pulmonary disease (COPD, 2/25, 8%), malignant tumors (2/25, 8%) and acute pancreatitis (1/25, 4%). (Table.1)

Organ dysfunction in COVID-19

In addition to affecting respiratory function, the most common organ damage outside the lungs was the heart, (18 patients' serum hypersensitive troponin I (cTnI) or/and Amino-terminal pro-brain natriuretic peptide (Pro-BNP) levels were increased (18/19, 94.7%)), followed by kidney (12 patients' serum blood urea nitrogen (BUN) or/and creatinine (Cr) levels were increased (12/25, 48%)) and liver (5 patients' serum Alanine transaminase (ALT) and aspartate aminotransferase (AST) levels were increased (5/25, 20%)). Besides, all the patients' albumin levels were decreased. (Table.2)

Inflammatory response in COVID-19

The routine blood test, procalcitonin (PCT), C-Reactive Protein (CRP) and Serum amyloid A (SAA) were used to reflect changes of inflammatory response in COVID-19. In the patients' last examination before death, white blood cell and neutrophil counts were elevated in 17 patients (17/25, 68%) and 18 patients (18/25, 72%), lymphocyte counts were decreased in 22 patients (22/25, 88%). Most patients had mild anemia, RBC and Hb levels were decreased in 20 (20/25, 80%) and 17 (17/25, 68%) patients respectively. Due to alimentary tract hemorrhage, the patient 17 had severe anemia. Most patients' PCT, CRP and SAA levels were elevated, the percentages were 90.5% (19/21), 85% (19/20) and 100% (21/21) respectively. (Table.3)

Specific biomarker that indicating poor prognosis

In order to screen for biomarker indicating poor prognosis, we observed the changes of biochemical indicators in all patients (if repeated measurements were present). The results showed that the levels of the last test of neutrophils (15/16, 93.8%), PCT (11/11, 100%), CRP (11/13, 84.6%), cTnI (8/9, 88.9%), D-Dimer (11/12, 91.6%) and lactate dehydrogenase (LDH) (9/9, 100%) were increased as compared to the first test, while the levels of lymphocytes were decreased (14/16, 87.5%). The SAA maintained a high level. Chest CT scan showed that the patients' pulmonary lesions were worse in the late stage than in the early stage (patient 3, patient 13 and patient 14). (Fig.1)

Discussion

In this study, we reported 25 death cases of with COVID-19. The clinical characters of these patients indicated that the age and underlying diseases were the most important risk factors for death. As concerning the underlying diseases, the most common one was hypertension, followed by diabetes, Heart disease, kidney disease, cerebral infarction, COPD, malignant tumors and acute pancreatitis.

The SARS-CoV-2 has been identified as one of a class of single-stranded enveloped 39 RNA viruses, belonging to the beta-coronaviruses genus of the *Coronaviridae* family (1). The analysis showed that both SARS-CoV-2 and the SARS-CoV shared a common ancestor that resembles the bat coronavirus HKU9-1 (8). And the severity of some cases with SARS-CoV-2 was similar to that of SARS-CoV (9). In the presents study, all the patients were died of respiratory failure, which indicated that the lung is the most common target organ of SARS-CoV-2.

Multiple organ dysfunction could also be observed, the most common organ damage outside the lungs was the heart, followed by kidney and liver. The results demonstrated that the death of the patient may be primarily related to impaired cardiopulmonary function. All the patients' albumin levels and 80% and 68% of patients' RBC and Hb levels were decreased, which indicates that malnutrition is common to severe patients.

COVID-19 is a viral disease characterized by normal or low white blood cell count and decreased lymphocyte count (10). In this study, increased white blood cell and neutrophils count were observed in 68% and 72% of patients. In addition, PCT levels were elevated in 90.5% of patients. PCT is sensitive indicator of bacterial infection (11). The results indicated that bacterial infections may play an important role in promoting the death of patients.

CRP is a useful marker and gauge of inflammation, it plays an important role in host defense against invading pathogens as well as in inflammation (12). SAA is a plasma protein that transports lipids during inflammation (13). In the present study, CRP and SAA were elevated before death in 85% and 100% of patients, suggesting that there is a severe inflammatory cascade in patients with COVID-19.

In order to screen out biochemical indicators that are meaningful for the diagnosis of disease progression, we consulted the laboratory test results of all the dead patients, among which 16 patients had repeated measurements. The SAA maintained a high level in all the patients, this result indicated that elevated SAA levels are closely related to the poor prognosis of patients. The

levels of the first test of neutrophils (93.8%), PCT (100%), CRP (84.6%), cTnI (88.9%), D-Dimer (91.6%) and LDH (100%) were increased as compared to the last test, while the levels of lymphocytes were decreased (87.5%), suggesting that the rising of neutrophils, PCT, CRP, cTnI, D-Dimer and LDH levels can be used as indicators of disease progression, as well as the decline of lymphocytes counts.

This was a small sample size retrospective study, which was limited by the small numbers of patients and by using a retrospective method. In particular, some important laboratory results were incomplete.

In conclusion, the age and underlying diseases (hypertension, diabetes, etc.) is the most important risk factors for death of COVID-19. Bacterial infections may play an important role in promoting the death of patients. Malnutrition is common to severe patients. Multiple organ dysfunction can be observed, the most common organ damage outside the lungs is the heart, followed by kidney and liver. The rising of neutrophils, SAA, PCT, CRP, cTnI, D-Dimer and LDH levels can be used as indicators of disease progression, as well as the decline of lymphocytes counts.

Contributors

ZG and BS made substantial contributions to the study concept and design. XL was in charge of the manuscript draft. LW took responsibility for obtaining ethical approval and collecting samples. FY and JZ made substantial contributions to data acquisition, analysis and interpretation. SY and LX reviewed the data. ZG made substantial revisions to the manuscript.

Declaration of interests

We declare no competing interests.

References:

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med*. 2020 2020-01-24.
2. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *LANCET*. 2020 2020-01-24.
3. Phan LT, Nguyen TV, Luong QC, Nguyen TV, Nguyen HT, Le HQ, et al. Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam. *N Engl J Med*. 2020 2020-01-28.

4. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*. 2020 2020-02-07.
5. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *LANCET*. 2020 2020-01-24.
6. Qiu S, Liu J, Xing F. 'Hints' in the killer protein gasdermin D: unveiling the secrets of gasdermins driving cell death. *CELL DEATH DIFFER*. 2017 2017-04-01;24(4):588-96.
7. National Health Commission of the People's Republic of China. Update on novel coronavirus-infected pneumonia situation as of 24:00 on February 13, 2020. <http://www.nhc.gov.cn/xcs/yqfkdt/202002/553ff43ca29d4fe88f3837d49d6b6ef1.shtml>
8. Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. *SCI CHINA LIFE SCI*. 2020 2020-01-21.
9. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *LANCET*. 2020 2020-01-30.
10. National Health Commission of China. New coronavirus pneumonia prevention and control program (4th edn). Jan 22, 2020. <http://www.gov.cn/zhengce/zhengceku/2020-01/28/5472673/files/0f96c10cc09d4d36a6f9a9f0b42d972b.pdf> (accessed Feb 4, 2020; in Chinese)
11. Schuetz P, Wirz Y, Sager R, Christ-Crain M, Stolz D, Tamm M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. *Cochrane Database Syst Rev*. 2017 2017-10-12;10:D7498.
12. Wu Y, Potempa LA, El KD, Filep JG. C-reactive protein and inflammation: conformational changes affect function. *BIOL CHEM*. 2015 2015-11-01;396(11):1181-97.
13. Frame NM, Kumanan M, Wales TE, Bandara A, Fandrich M, Straub JE, et al. Structural Basis for Lipid Binding and Function by an Evolutionarily Conserved Protein, Serum Amyloid A. *J MOL BIOL*. 2020 2020-02-06.

Table.1 General clinical characteristics of 25 death cases

ID	Gender	Age	Course	Respirator	Underlying diseases
patient1	F	55	17	Y	Diabetes
patient2	M	62	11	Y	Diabetes, Hypertension
patient3	F	81	17	Y	Hypertension, Heart disease
patient4	F	72	10	Y	Diabetes, Hypertension, COPD, CRF, Heart disease
patient5	F	83	7	Y	Diabetes, Hypertension, CRF, Heart disease
patient6	M	70	8	Y	Hypertension
patient7	M	73	9	Y	Heart disease
patient8	F	74	8	Y	Heart disease
patient9	M	82	7	Y	Hypertension, Heart disease
patient10	M	78	10	Y	Hypertension, Hepatitis B
patient11	F	78	9	Y	Hypertension
patient12	F	67	7	Y	Diabetes
patient13	M	94	14	Y	Hypertension
patient14	F	69	13	Y	Heart disease
patient15	M	90	9	Y	Hypertension, Cerebral infarction
patient16	F	75	7	Y	Diabetes, Hypertension Diabetes, Hypertension, Alimentary tract hemorrhage,
patient17	F	56	7	Y	Nephrotic syndrome
patient18	F	59	11	Y	Diabetes, Hypertension
patient19	M	56	17	Y	Diabetes, Hypertension, Cerebral infarction, NAFLD
patient20	M	74	8	Y	Hypertension, Cerebral infarction
patient21	F	55	10	N	Pulmonary nodules, after lobectomy
patient22	F	64	20	N	lung cancer, chemotherapy
patient23	F	74	19	Y	lymphoma, chemotherapy, interstitial pneumonia
patient24	F	56	5	Y	Hypertension, acute pancreatitis, ureteral calculus, CRF
patient25	M	100	4	Y	Heart disease, COPD, Diabetes, CRF

Table.2 Changes of organ function of 25 death cases

ID	ALT (U/L)	AST (U/L)	ALB (g/L)	BUN (mmol/L)	Cr (μmol/L)	cTnI (ng/mL)	Pro-BNP (pg/mL)
patient1	16	30	26.18	7.81	43	0.205	8304
patient2	49	67	27.91	33.43	428	16.342	7961
patient3	22	34	26.8	7.22	47	0.789	8023
patient4	7	18	29.74	18.07	497	0.057	6914
patient5	27	56	28.6	20.75	209	4.129	5725
patient6	70	107	28.51	14.36	113	0.316	1182
patient7	31	53	34.58	N/A	N/A	N/A	429
patient8	14	34	35.98	6.07	58	N/A	90
patient9	33	38	31.7	9.29	63	N/A	1658
patient10	51	81	35.19	12.67	110	5.42	940
patient11	21	38	37.86	N/A	242	N/A	N/A
patient12	27	36	36.4	5.57	51	5.804	2450
patient13	44	62	36.5	8.66	73	0.225	2394
patient14	24	27	29.9	5.14	51	N/A	N/A
patient15	17	43	34.4	4.89	60	N/A	N/A
patient16	21	37	36.1	9.73	49	0.034	2866
patient17	16	39	23.8	23.92	69	0.13	12733
patient18	68	32	28.7	6.67	43	N/A	N/A
patient19	515	1082	32.81	16.4	175	92.43	18019
patient20	48	59	33.4	10.21	71	0.017	822
patient21	26	32	36.1	2.9	51	N/A	N/A
patient22	20	20	33.8	7.59	26	0.006	230
patient23	13	24	32.5	1.8	29	N/A	N/A
patient24	17	23	28.5	18.53	580	1.364	N/A
patient25	13	29	37.16	9.42	119	N/A	N/A
Normal							<75y:0-125
range	9-50	15-40	40-55	3.6-9.5	57-111	0-0.04	>75y:0-450

N/A: Not available

Table.3 Changes of inflammatory markers of 25 death cases

ID	WBC (cells/L)	NEU (cells/L)	LYM (cells/L)	RBC (cells/L)	Hb (g/L)	PLT (cells/L)	PCT (ng/mL)	CRP (mg/L)	SAA (mg/L)
patient1	10.84	10.41	0.31	3.64	112	194	1.43	86	>300
patient2	17.91	17.01	0.23	3.92	137	39	75	96.2	>300
patient3	14.04	13.72	0.13	3.79	122	125	1.33	174	>300
patient4	10.08	9	0.52	2.44	68	167	3.55	178	>300
patient5	2,98	2.63	0.26	2.77	91	64	N/A	82.8	>300
patient6	16.74	15.07	0.28	3.83	128	226	2.09	203	>300
patient7	10.27	8.9	0.69	4.56	140	233	N/A	124.3	>300
patient8	8.68	7.48	0.72	3.97	120	224	0.178	141	>300
patient9	11.76	10.98	0.41	5.45	174	262	0.228	N/A	N/A
patient10	13.93	12.41	1.12	4.05	134	175	0.376	180	>300
patient11	9.58	8.13	0.81	2.65	77	338	N/A	N/A	N/A
patient12	12.61	10.76	1.09	4.58	139	139	0.126	51.4	>300
patient13	5.63	4.92	0.53	3.36	106	150	0.139	120	>300
patient14	11.01	10.31	0.55	3.69	115	24	N/A	110	>300
patient15	5.65	4,56	0.59	4.02	130	128	0.04	33.8	202.41
patient16	13.35	12.62	0.52	4.69	150	239	0.12	39	>300
patient17	18.77	17.31	1.1	1.45	45	133	1.98	74	>300
patient18	6.33	5.39	0.48	4.2	123	139	0.08	7.6	73.75
patient19	9.53	9.25	0.16	2.6	84	146	1.12	N/A	>300
patient20	20.17	17.92	1.43	4.49	139	201	0.3	N/A	N/A
patient21	3.98	2.99	0.68	3.82	121	121	0.16	148.1	>300
patient22	12.7	12.19	0.14	3.98	128	120	0.11	68	>300
patient23	2.62	2	0.17	2.67	87	92	0.36	80.7	>300
patient24	17.69	16.36	0.53	3.78	101	200	1.83	N/A	N/A
patient25	2.25	1.81	0.27	3.69	115	152	3.49	41.6	144.16
	3.5-9.5	1.8-6.3	1.1-3.2	4.3-5.8		125-350			
Normal range	($\times 10^9$)	($\times 10^9$)	($\times 10^9$)	($\times 10^{12}$)	130-175	($\times 10^9$)	0-0.1	0-10	0-10


WBC: white blood cells, NEU: neutrophils, LYM: lymphocytes, RBC: red blood cells, Hb: hemoglobin, PLT: blood platelet. The detection upper limit of SAA is 300 mg/L. N/A: Not available.

Table.4 Specific biomarker that indicating poor prognosis

ID	NEU (cells/L)		LYM (cells/L)		PCT (ng/mL)		CRP (mg/mL)		SAA (mg/mL)		cTnI (ng/mL)		D-Dime (mg/L)		LDH (U/L)	
	First	Last	First	Last	First	Last	First	Last	First	Last	First	Last	First	Last	First	Last
patient1	4.39	10.41	0.35	0.31	0.02	1.44	14.1	86	>300	>300	0.015	0.205	0.49	56.47	401	631
patient2	7.27	17.01	0.32	0.23	1.42	75	83.5	96.2	>300	N/A	0.091	16.34	4.39	115.3	758	N/A
patient3	1.29	13.72	0.49	0.13	0.13	1.33	52.9	174	5	>300	0.071	0.293	35.56	49.52	331	604
patient4	8.9	9	0.9	0.52	0.89	3.55	211	178	>300	>300	0.075	0.057	2.82	1.53	248	323
patient5	4.07	2.63	0.2	0.26	N/A	N/A	76.1	0.5	>300	>300	0.538	4.129	N/A	N/A	N/A	N/A
patient6	7.95	15.07	0.51	0.28	N/A	2.09	201	203	>300	>300	N/A	0.316	N/A	20.33	N/A	N/A
patient13	3.7	4.92	1.4	0.53	0.07	0.139	58	120	253	>300	0.177	0.225	0.35	13.9	294	535
patient14	4.74	10.31	0.84	0.55	0.02	N/A	19.9	110	>300	>300	N/A	N/A	1.31	49.8	397	510
patient16	11.52	12.62	0.92	0.52	0.12	N/A	39	N/A	>300	N/A	0.34	0.34	1.04	3.59	455	N/A
patient17	14.49	17.31	1.2	1.1	0.24	1.98	56.8	74	>300	>300	0.006	0.13	20.57	1.16	256	N/A
patient18	2.5	5.39	0.54	0.48	0.08	0.11	7.6	18.4	73.75	>300	N/A	N/A	0.43	5.95	237	478
patient19	2.89	9.25	0.7	0.16	0.11	1.12	4.9	N/A	11.11	>300	0.06	92.43	0.14	155	252	669
patient21	2.02	2.99	0.76	0.68	0.07	0.16	31.8	148.1	>300	>300	N/A	N/A	N/A	1.33	N/A	278
patient22	9.08	12.19	0.06	0.14	0.09	0.11	52	32.7	>300	187.8	0.006	N/A	3	2.33	321	322
patient23	8.88	2	0.26	0.17	0.13	0.36	19.2	80.7	176.3	>300	N/A	N/A	0.41	4.12	347	405
patient24	8.08	16.36	1.07	0.53	N/A	1.83	N/A	N/A	N/A	N/A	N/A	N/A	N/A	13.09	N/A	N/A
Normal range	1.8-6.3 ×10 ⁹		1.1-3.2 ×10 ⁹		0-0.1		0-10		0-10		0-0.04		0-0.55		120-250	

NEU: neutrophils, LYM: lymphocytes, N/A: Not available.

Fig.1 Chest CT scans of patient 3, patient 13 and patient 14



A1: the early stage Chest CT scan of Patient 3; A2: the late stage Chest CT scan of Patient 3;
B1: the early stage Chest CT scan of Patient 13; B2: the late stage Chest CT scan of Patient
13; C1: the early stage Chest CT scan of Patient 14; C2: the late stage Chest CT scan of
Patient 14.